The FDA has notified healthcare professionals of reports of clinically significant liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, occurring as early as six days after the first dose of Tysabri.

References and Resources
FDA Public Health Update
Tysabri should be discontinued in patients with jaundice or other evidence of significant liver injury

Sponsored by The Doctor’s Channel